Arch Therapeutics, Inc. (ARTH) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 Framingham, MA, 美国. 现任CEO为 Terrence W. Norchi.
ARTH 拥有 IPO日期为 2013-01-02, 8 名全职员工, 在 Other OTC, 市值为 $444.00.
Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. The company develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. Its flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. The company was founded in 2006 and is based in Framingham, Massachusetts.
